<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activated protein C (APC) protects neurons and endothelium via protease activated receptor (PAR)1, PAR3 and endothelial protein C receptor </plain></SENT>
<SENT sid="1" pm="."><plain>APC is neuroprotective in <z:hpo ids='HP_0001297'>stroke</z:hpo> models </plain></SENT>
<SENT sid="2" pm="."><plain><z:mp ids='MP_0001914'>Bleeding</z:mp> complications may limit the pharmacologic utility of APC </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we compared the 3K3A-APC mutant with 80% reduced <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> activity and <z:mp ids='MP_0002169'>wild-type</z:mp> (wt)-APC </plain></SENT>
<SENT sid="4" pm="."><plain>Murine 3K3A-APC compared with wt-APC protected mouse cortical neurons from <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> with twofold greater efficacy and more potently reduced <z:chebi fb="0" ids="31882">N-methyl-D-aspartate</z:chebi> excitotoxic lesions in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>Human 3K3A-APC protected human brain endothelial cells (BECs) from oxygen/<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation with 1.7-fold greater efficacy than wt-APC </plain></SENT>
<SENT sid="6" pm="."><plain>3K3A-APC neuronal protection required PAR1 and PAR3, as shown by using PAR-specific blocking antibodies and PAR1- and PAR3-deficient cells and mice </plain></SENT>
<SENT sid="7" pm="."><plain>BEC protection required endothelial protein C receptor and PAR1 </plain></SENT>
<SENT sid="8" pm="."><plain>In neurons and BECs, 3K3A-APC blocked caspase-9 and -3 activation and induction of p53, and decreased the Bax/Bcl-2 pro-apoptotic ratio </plain></SENT>
<SENT sid="9" pm="."><plain>After distal middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (dMCAO) in mice, murine 3K3A-APC compared with vehicle given 4:00 h after dMCAO improved the functional outcome and reduced the infarction volume by 50% within 3 days </plain></SENT>
<SENT sid="10" pm="."><plain>3K3A-APC compared with wt-APC multi-dosing therapy at 12:00 h, 1, 3, 5 and 7 days after dMCAO significantly improved functional recovery and reduced the infarction volume by 75% and 38%, respectively, within 7 days </plain></SENT>
<SENT sid="11" pm="."><plain>The wt-APC, but not 3K3A-APC, significantly increased the risk of <z:mp ids='MP_0001916'>intracerebral bleeding</z:mp> as indicated by a 50% increase in <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels in the ischemic hemisphere </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, 3K3A-APC offers a new approach for safer and more efficacious treatments of <z:e sem="disease" ids="C0524851" disease_type="Disease or Syndrome" abbrv="">neurodegenerative disorders</z:e> and <z:hpo ids='HP_0001297'>stroke</z:hpo> with APC </plain></SENT>
</text></document>